

RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE QUARTER AND TWELVE MONTHS ENDED JUNE 30, 2013

SAN DIEGO, August 1, 2013 - ResMed Inc. (NYSE: RMD) today announced record revenue and income for the quarter ended June 30, 2013. Revenue for the quarter ended June 30, 2013 was \$414.6 million, an 11% increase (also an 11% increase on a constant currency basis) over the quarter ended June 30, 2012. For the quarter ended June 30, 2013, GAAP income from operations was \$86.2 million, while GAAP net income was \$73.0 million or \$0.50 per diluted share. These results were impacted by a \$24.8 million (\$17.7 million, net of tax) charge for our previously announced Sydney University education, research and settlement expenses. For the quarter ended June 30, 2013, non-GAAP operating income and non-GAAP net income were \$110.9 million and \$90.7 million, an increase of 24% and 18%, respectively, compared to the quarter ended June 30, 2012 (non-GAAP measures exclude the impact of the charge for Sydney University education, research and settlement expenses, as described below). Non-GAAP diluted earnings per share for the quarter ended June 30, 2013 were \$0.62, an increase of 17% compared to the quarter ended June 30, 2012.

SG&A expenses were \$115.1 million for the quarter ended June 30, 2013, an increase of \$9.1 million, or 9% (also a 9% increase on a constant currency basis) compared to the quarter ended June 30, 2012. SG&A costs were 27.8% of revenue in the quarter ended June 30, 2013, compared to 28.5% for the quarter ended June 30, 2012.

R&D expenses were \$31.4 million for the quarter ended June 30, 2013, or 7.6% of revenue. R&D expenses increased by 12% (a 14% increase on a constant currency basis) compared to the quarter ended June 30, 2012. R&D expenses were favorably impacted by the depreciation of the Australian dollar against the U.S. dollar.

The company amortized acquired intangibles of \$2.5 million (\$1.9 million, net of tax) during the quarter ended June 30, 2013. Stock-based compensation costs incurred during the quarter ended June 30, 2013 of \$10.5 million (\$6.6 million, net of tax) consisted of expenses associated with stock options, restricted stock units, and our employee stock purchase plan.

As disclosed in our May press release, we reached an agreement with the University of Sydney ("University") to pay \$24.8 million for the establishment of two perpetual academic chairs, the funding of future research in the fields of sleep medicine and biomedical engineering and the settlement of legal proceedings between the parties. We have expensed the full amount of \$24.8 million (\$17.7 million, net of tax) in the current quarter within our operating expenses and we have separately disclosed the amount as an education, research and settlement charge.

For the year ended June 30, 2013, revenue was \$1.5 billion, an increase of 11% over the year ended June 30, 2012 (a 12% increase on a constant currency basis). For the year ended June 30, 2013, GAAP net income was \$307.1 million, an increase of 21% compared to the year ended June 30, 2012. GAAP diluted earnings per share for the year ended June 30, 2013 were \$2.10, an increase of 23% compared to the year ended June 30, 2012. For the year ended June 30, 2013, non-GAAP operating income and non-GAAP diluted earnings per share were \$379.6 million and \$2.22, an increase of 29% and 30%, respectively, compared to the year ended June 30, 2012.

Additionally, the Board of Directors has today declared a quarterly dividend of \$0.25 per share, which will have a record date of August 20, 2013, and be payable on September 17, 2013. The dividend will be paid in U.S. currency to holders of ResMed's common stock trading on the New York Stock Exchange (NYSE). Holders of CHESS Depositary Instruments (CDIs) trading on the Australian Securities Exchange (ASX) will receive an equivalent amount in Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares. Because the two exchanges have different settlement and transfer procedures, the exdividend date will be August 14, 2013 for CDI holders and August 16, 2013 for common stock holders. As a result of these differences, ResMed has received a waiver from the ASX's settlement operating rules, which will allow ResMed to defer processing conversions between its common stock and CDI registers from August 14, 2013 through August 20, 2013, inclusive.

Mick Farrell, chief executive officer, commented, "In the fourth quarter of fiscal 2013 we showed strong year-over-year growth on both top and bottom lines. Revenue in the Americas increased by 11% over the prior year's quarter to \$230.3 million for Q4. Revenue in Europe and Asia-Pac combined reached \$184.3 million, an increase of 12% (an 11% increase on a constant currency basis) over the prior year's quarter. Non-GAAP operating profit for the June quarter was \$110.9 million, cash flow from operations was a record \$123.9 million, while gross margin was 62.7%, all demonstrating excellent operating performance. We have also announced today that our quarterly dividend has increased by 47% to \$0.25 per share. Additionally, during the quarter, we repurchased 1.5 million shares, at a cost of \$72.7 million. The increased dividend and the ongoing share buy-back program demonstrate our commitment to a robust capital management program.

"We had many other accomplishments this quarter to report. The Serve-HF heart failure trial is fully enrolled with over 1,325 patients. In addition, we have finalized the protocol for our U.S. heart failure trial, CAT-HF and intend to begin enrollment this fall. We introduced VPAP™ COPD, a first-of-its-kind respiratory product for those suffering from chronic obstructive pulmonary disease (COPD), and it is already doing well. We launched the Quattro™ Air full face mask globally. This new mask is the lightest full face mask on the market, weighing in at just 3.3 ounces, making it 45 percent lighter than its predecessor and the current #1 seller in the U.S., the Mirage Quattro™. During the quarter, we also launched ResMed's SleepSeeker – which is an online tool to increase patient engagement in therapy for sleep-disordered breathing. With SleepSeeker, patients will be able to view their own therapy data, including time on therapy, any apnea or hypopnea events, and any mask leaks during the night. Our aim is to improve therapy compliance through better patient engagement. These solutions will help in the management and control of various chronic diseases associated with both COPD and untreated sleep-disordered breathing."

About ResMed

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.

ResMed will host a conference call at 1:30 p.m. U.S. Pacific Time today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's website at www.resmed.com or by dialing 847-585-4405 (domestic) or +1 847-585-4405 (international) and entering conference pass code no. 35164091. Please allow extra time prior to the call to visit the website and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 30 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing 630-652-3042 (domestic) and +1 630-652-3042 (international) and entering conference I.D. No. 35164091.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc., San Diego, at (858) 836-5971; Brett Sandercock at ResMed Limited, Sydney, on (+612) 8884-2090; or by visiting the Company's multilingual website at www.resmed.com.

Statements contained in this release that are not historical facts are "forward-looking" statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development and new markets for the Company's products, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Those risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's Website.

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Statements of Income (Unaudited) (In US\$ thousands, except per share data)

	Three Months Ended June 30,		Twelve Months Ended June 30,	
	2013	2012	2013	2012
Net revenue Cost of sales	\$414,607 154,759	\$371,929 145,460	\$1,514,457 573,800	\$1,368,515 547,780
Gross profit	259,848	226,469	940,657	820,735
Operating expenses: Selling, general and administrative Research and development Education, research and settlement charge (1)	115,057 31,390 24,765	105,909 27,911 -	430,802 120,124 24,765	402,621 109,733 -
Amortization of acquired intangible assets	2,471	2,919	10,142	13,974
Total operating expenses	173,683	136,739	585,833	526,328
Income from operations ⁽¹⁾	86,165	89,730	354,824	294,407
Other income (expenses), net: Interest income (expense), net Other, net	7,439 (5,777)	7,326 1,454	32,486 (2,191)	29,080 8,458
Total other income (expenses), net	1,662	8,780	30,295	37,538
Income before income taxes Income taxes	87,827 14,814	98,510 21,663	385,119 77,986	331,945 77,095
Net income ⁽¹⁾	\$73,013	\$76,847	\$307,133	\$254,850
Basic earnings per share Diluted earnings per share (1) Non-GAAP diluted earnings per share, excluding the impact of the education, research and settlement charge (1)	\$0.51 \$0.50 \$0.62	\$0.54 \$0.53 \$0.53	\$2.15 \$2.10 \$2.22	\$1.75 \$1.71 \$1.71
Basic shares outstanding Diluted shares outstanding	142,669 146,115	142,788 146,099	142,954 146,410	145,901 149,316

⁽¹⁾ See reconciliation of non-GAAP financial measures in table at end of press release.

RESMED INC AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(In US\$ thousands except share and per share data)

	June 30,	June 30, 2012
Assets	2013	2012
Current assets:		
Cash and cash equivalents	\$876,048	\$809,541
Accounts receivable, net	318,349	283,160
Inventories	145,847	174,351
Prepayments, deferred income taxes and other current assets	108,605	94,099
Total current assets	1,448,849	1,361,151
Property, plant and equipment, net	411,433	434,363
Goodwill	274,829	256,209
Other intangibles	49,639	54,827
Deferred income taxes and other non-current assets	25,971	31,319
Total non-current assets	761,872	776,718
Total assets	\$2,210,721	\$2,137,869
LIABILITIES AND STOCKHOLDERS' EQUITY		
Current liabilities:		
Accounts payable	60,688	55,006
Accrued expenses	137,674	127,381
Deferred revenue	44,953	41,563
Income taxes payable	30,090	27,777
Deferred income taxes	627	1,073
Current portion of long-term debt	300,017	52
Total current liabilities	574,049	252,852
Non-current liabilities:		
Deferred income taxes	9,895	8,843
Deferred revenue	11,928	14,384
Income taxes payable	3,564	3,380
Non-current portion of long-term debt	769	250,783
Total non-current liabilities	26,156	277,390
Total liabilities	600,205	530,242
Stockholders' Equity:		
Common stock	568	568
Additional paid-in capital	1,025,064	899,717
Retained earnings	1,576,641	1,366,712
Treasury stock	(1,083,845)	(895,826)
Accumulated other comprehensive income	92,088	236,456
Total stockholders' equity	1,610,516	1,607,627
Total liabilities and stockholders' equity	\$2,210,721	\$2,137,869

Reconciliation of Non-GAAP Financial Measures (Unaudited)

(In US\$ thousands, except share and per share data)

The measure, "non-GAAP operating income" is reconciled with GAAP income from operations in the table below:

	Three Months Ended June 30,		Year Ended	
			June 30,	
	2013	2012	2013	2012
GAAP income from operations	86,165	89,730	354,824	294,407
Education, research and settlement charge (A)	24,765	-	24,765	-
Non-GAAP operating income (excluding the impact of the education, research and settlement charge)	110,930	89,730	379,589	294,407

The measure, "non-GAAP net income" and "non-GAAP diluted earnings per share" are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

	Three Months Ended June 30,		Year Ended June 30,	
	2013	2012	2013	2012
GAAP net income	73,013	76,847	307,133	254,850
Education, research and settlement charge, net of tax (A)	17,707	-	17,707	-
Non-GAAP net income (excluding the impact of the education, research and settlement charge)	90,720	76,847	324,840	254,850
Diluted shares outstanding	146,115	146,099	146,410	149,316
GAAP diluted earnings per share	\$0.50	\$0.53	\$2.10	\$1.71
Non-GAAP diluted earnings per share (excluding the impact of the education, research and settlement charge)	\$0.62	\$0.53	\$2.22	\$1.71

⁽A) The education, research and settlement charge relates to an agreement with the University of Sydney ("University") to pay A\$25 million (US\$24.8 million) for the following.

- A\$10 million for the establishment of two perpetual academic chairs called the ResMed Chair of Sleep
 Medicine for sleep-disordered breathing with a focus on chronic disease and the ResMed Chair of
 Biomedical Engineering with an emphasis on bioinformatics research.
- A\$5 million in equal installments, over five years, to be used by the University to support research in the fields of sleep medicine and biomedical engineering.
- A\$10 million in settlement of proceedings between the parties, including A\$1.25 million for the release from the proceedings and A\$8.75 million for royalties payable under the license agreement.

ResMed believes that presenting diluted earnings per share, excluding the impact of the charge for Sydney University education, research and settlement expenses is an additional measure of performance that investors can use to compare operating results between reporting periods. We believe the expenses are not associated with the Company's normal operating business.

Management of the Company uses non-GAAP information internally in planning, forecasting, and evaluating the Company's results of operations in the current period and in comparing it to past periods. Management believes that this information also provides investors better insight in evaluating the Company's earnings performance from core operations and provides consistency in financial reporting. Our use of non-GAAP earnings is intended to supplement, and not to replace, our presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under GAAP. We compensate for the inherent limitations of non-GAAP measures by not relying exclusively on non-GAAP measures, but rather by using such information to supplement GAAP financial measures.